Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
On March 12, 2026, Plus Therapeutics, Inc. (Nasdaq: PSTV) shared its financial results for the fourth quarter and full year ending on December 31, 2025. Plus, a healthcare firm specializing in precision diagnostics and radiopharmaceuticals for CNS cancers, outlined recent and forthcoming business highlights.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments